Moxley, R.A.; Francis, D.H.; Tamura, M.; Marx, D.B.; Santiago-Mateo, K.; Zhao, M.
Efficacy of Urtoxazumab (TMA-15 Humanized Monoclonal Antibody Specific for Shiga Toxin 2) Against Post-Diarrheal Neurological Sequelae Caused by Escherichia coli O157:H7 Infection in the Neonatal Gnotobiotic Piglet Model. Toxins 2017, 9, 49.
https://doi.org/10.3390/toxins9020049
AMA Style
Moxley RA, Francis DH, Tamura M, Marx DB, Santiago-Mateo K, Zhao M.
Efficacy of Urtoxazumab (TMA-15 Humanized Monoclonal Antibody Specific for Shiga Toxin 2) Against Post-Diarrheal Neurological Sequelae Caused by Escherichia coli O157:H7 Infection in the Neonatal Gnotobiotic Piglet Model. Toxins. 2017; 9(2):49.
https://doi.org/10.3390/toxins9020049
Chicago/Turabian Style
Moxley, Rodney A., David H. Francis, Mizuho Tamura, David B. Marx, Kristina Santiago-Mateo, and Mojun Zhao.
2017. "Efficacy of Urtoxazumab (TMA-15 Humanized Monoclonal Antibody Specific for Shiga Toxin 2) Against Post-Diarrheal Neurological Sequelae Caused by Escherichia coli O157:H7 Infection in the Neonatal Gnotobiotic Piglet Model" Toxins 9, no. 2: 49.
https://doi.org/10.3390/toxins9020049
APA Style
Moxley, R. A., Francis, D. H., Tamura, M., Marx, D. B., Santiago-Mateo, K., & Zhao, M.
(2017). Efficacy of Urtoxazumab (TMA-15 Humanized Monoclonal Antibody Specific for Shiga Toxin 2) Against Post-Diarrheal Neurological Sequelae Caused by Escherichia coli O157:H7 Infection in the Neonatal Gnotobiotic Piglet Model. Toxins, 9(2), 49.
https://doi.org/10.3390/toxins9020049
